Worldwide, cancer is a serious threat to the health of citizens of every country, with the incidence and mortality increasing year by year. Cisplatin is the first-line anticancer drug commonly used in clinics and is widely used for the treatment of solid tumors including lung, gastric, liver, bladder, and ovarian cancer. Although cisplatin-based chemotherapy has a high clinical response efficacy, patients will inevitably develop drug resistance after repeated using, leading to severe restrictions of its application. Circular RNAs (circRNAs) are a promising class of non-coding RNAs capable of promoting or suppressing cancer via functioning as miRNAs sponges. Recently, an increasing amount of evidence shows that circRNAs are closely related to the cisplatin resistance of cancers. Therefore, standing at the perspective of the cisplatin chemotherapy resistance, this paper reviews the research progress of circRNAs related to cisplatin resistance of various cancers.

中文翻译：

---

circRNA 对癌症顺铂化疗耐药的贡献的最新进展。

在世界范围内，癌症对各国公民的健康构成严重威胁，发病率和死亡率逐年上升。顺铂是临床常用的一线抗癌药物，广泛用于治疗肺癌、胃癌、肝癌、膀胱癌、卵巢癌等实体瘤。以顺铂为基础的化疗虽然具有较高的临床疗效，但患者反复使用后难免产生耐药性，严重限制了其应用。环状 RNA (circRNA) 是一类很有前途的非编码 RNA，能够通过充当 miRNA 海绵来促进或抑制癌症。最近，越来越多的证据表明，circRNAs与癌症的顺铂耐药密切相关。所以，